Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 3
2005 1
2007 1
2008 4
2009 2
2010 1
2011 1
2012 1
2013 1
2014 4
2015 12
2016 4
2017 2
2018 6
2019 4
2020 7
2021 5
2022 6
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

59 results
Results by year
Filters applied: . Clear all
Page 1
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
Scheffler M, Ihle MA, Hein R, Merkelbach-Bruse S, Scheel AH, Siemanowski J, Brägelmann J, Kron A, Abedpour N, Ueckeroth F, Schüller M, Koleczko S, Michels S, Fassunke J, Pasternack H, Heydt C, Serke M, Fischer R, Schulte W, Gerigk U, Nogova L, Ko YD, Abdulla DSY, Riedel R, Kambartel KO, Lorenz J, Sauerland I, Randerath W, Kaminsky B, Hagmeyer L, Grohé C, Eisert A, Frank R, Gogl L, Schaepers C, Holzem A, Hellmich M, Thomas RK, Peifer M, Sos ML, Büttner R, Wolf J. Scheffler M, et al. Among authors: fassunke j. J Thorac Oncol. 2019 Apr;14(4):606-616. doi: 10.1016/j.jtho.2018.12.013. Epub 2018 Dec 31. J Thorac Oncol. 2019. PMID: 30605727 Free article.
[Molecular diagnostics of cytological specimens].
Fassunke J, Ball M, Engels M. Fassunke J, et al. Pathologe. 2020 Feb;41(1):39-45. doi: 10.1007/s00292-019-00733-3. Pathologe. 2020. PMID: 31932945 Review. German.
Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors.
Borchmann S, Selenz C, Lohmann M, Ludwig H, Gassa A, Brägelmann J, Lohneis P, Meder L, Mattlener J, Breid S, Nill M, Fassunke J, Wisdom AJ, Compes A, Gathof B, Alakus H, Kirsch D, Hekmat K, Büttner R, Reinhardt HC, Hallek M, Ullrich RT. Borchmann S, et al. Among authors: fassunke j. J Immunother Cancer. 2022 Oct;10(10):e004781. doi: 10.1136/jitc-2022-004781. J Immunother Cancer. 2022. PMID: 36223955 Free PMC article.
Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications.
Scheffler M, Wiesweg M, Michels S, Nogová L, Kron A, Herold T, Scheel AH, Metzenmacher M, Eberhardt WE, Reis H, Fassunke J, Darwiche K, Aigner C, Schaufler D, Riedel R, Fischer R, Koleczko S, Schildhaus HU, Merkelbach-Bruse S, Schmid KW, Büttner R, Wolf J, Schuler M. Scheffler M, et al. Among authors: fassunke j. Lung Cancer. 2022 Jun;168:10-20. doi: 10.1016/j.lungcan.2022.04.006. Epub 2022 Apr 16. Lung Cancer. 2022. PMID: 35461051
Plasma Proteomics Enable Differentiation of Lung Adenocarcinoma from Chronic Obstructive Pulmonary Disease (COPD).
Bracht T, Kleefisch D, Schork K, Witzke KE, Chen W, Bayer M, Hovanec J, Johnen G, Meier S, Ko YD, Behrens T, Brüning T, Fassunke J, Buettner R, Uszkoreit J, Adamzik M, Eisenacher M, Sitek B. Bracht T, et al. Among authors: fassunke j. Int J Mol Sci. 2022 Sep 24;23(19):11242. doi: 10.3390/ijms231911242. Int J Mol Sci. 2022. PMID: 36232544 Free PMC article.
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer.
Schaufler D, Ast DF, Tumbrink HL, Abedpour N, Maas L, Schwäbe AE, Spille I, Lennartz S, Fassunke J, Aldea M, Besse B, Planchard D, Nogova L, Michels S, Kobe C, Persigehl T, Westphal T, Koleczko S, Fischer R, Weber JP, Altmüller J, Thomas RK, Merkelbach-Bruse S, Gautschi O, Mezquita L, Büttner R, Wolf J, Peifer M, Brägelmann J, Scheffler M, Sos ML. Schaufler D, et al. Among authors: fassunke j. NPJ Precis Oncol. 2021 Dec 17;5(1):102. doi: 10.1038/s41698-021-00241-9. NPJ Precis Oncol. 2021. PMID: 34921211 Free PMC article.
Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue.
Vollbrecht C, Hoffmann I, Lehmann A, Merkelbach-Bruse S, Fassunke J, Wagener-Ryczek S, Ball M, Dimitrova L, Hartmann A, Stöhr R, Erber R, Weichert W, Pfarr N, Bohlmann L, Jung A, Dietmaier W, Dietel M, Horst D, Hummel M. Vollbrecht C, et al. Among authors: fassunke j. Virchows Arch. 2022 Nov 11. doi: 10.1007/s00428-022-03445-x. Online ahead of print. Virchows Arch. 2022. PMID: 36367572
Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy.
Kron A, Scheffler M, Heydt C, Ruge L, Schaepers C, Eisert AK, Merkelbach-Bruse S, Riedel R, Nogova L, Fischer RN, Michels S, Abdulla DSY, Koleczko S, Fassunke J, Schultheis AM, Kron F, Ueckeroth F, Wessling G, Sueptitz J, Beckers F, Braess J, Panse J, Grohé C, Hamm M, Kabitz HJ, Kambartel K, Kaminsky B, Krueger S, Schulte C, Lorenz J, Lorenzen J, Meister W, Meyer A, Kappes J, Reinmuth N, Schaaf B, Schulte W, Serke M, Buettner R, Wolf J. Kron A, et al. Among authors: fassunke j. J Thorac Oncol. 2021 Apr;16(4):572-582. doi: 10.1016/j.jtho.2020.11.017. Epub 2020 Dec 9. J Thorac Oncol. 2021. PMID: 33309988 Free article.
[Chances and risks of blood-based molecular pathological analysis of circulating tumor cells (CTC) and cell-free DNA (cfDNA) in personalized cancer therapy: positional paper from the study group on liquid biopsy of the working group for molecular pathology in the German Society of Pathology (DGP)].
Dahl E, Jung A, Fassunke J, Hummel M, Penzel R, Dietmaier W, Laßmann S. Dahl E, et al. Among authors: fassunke j. Pathologe. 2015 Feb;36(1):92-7. doi: 10.1007/s00292-014-2069-x. Pathologe. 2015. PMID: 25533324 Review. German. No abstract available.
59 results